About
Atrogi is a clinical-stage biotechnology company developing first-in-class, once-daily oral small-molecule therapies targeting the beta-2 adrenergic receptor for metabolic disorders including type 2 diabetes, obesity, and muscle-wasting. Its lead candidate ATR-258 has completed Phase I and is ready for Phase II clinical trials.
Explore Atrogi's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.